{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "HAE",
  "name": "Haemonetics Corporation",
  "url": "https://frontierpicks.com/dossiers/HAE/",
  "json_url": "https://frontierpicks.com/dossiers/HAE.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a4",
    "n": 4
  },
  "current_thesis": "Legacy medtech pivot moved from promised to reported: the 2026-08-06 Q1 FY2027 beat ($339.4M vs $327.9M, adj EPS $1.14 vs $1.08) turned Interventional Technologies positive (+2.8% organic vs −10.3% in Q4) and lifted FY2027 organic guidance to +4–7%. Six targets rose inside 48 hours; at $90.80 the controversy is settled and the next dated test is ~November.",
  "invalidation_trigger": "A weekly close below $85 surrenders the entire 2026-08-06 print reaction and returns price to the pre-earnings $77–$85 congestion; secondarily, a Q2 FY2027 print with Interventional Technologies back to negative organic growth or the raised +4–7% organic FY range left unchanged.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "medtech-diagnostics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Fiscal year ends late March. FY2027 contains a 53rd week worth roughly 2 points of reported revenue growth, so reported and organic figures diverge all year.",
    "From Q1 FY2027 the company reports two segments — Apheresis (Plasma plus Other) and MedSurg (Blood Management Technologies plus Interventional Technologies). Pre-2026 segment history is not directly comparable.",
    "FY2027 guidance assumes zero revenue from PerQseal Elite, still under FDA review; any clearance is incremental to the raised plan.",
    "Vivasure Medical (closed 2026-01-09, $166.1M per the Q1 FY2027 10-Q) carries up to EUR 85M of contingent consideration; purchase accounting is still preliminary.",
    "$700M of 2.5% convertible notes due 2029 remain outstanding at a ~$117.12 conversion price, against total debt of $1,174.2M at 2026-06-27.",
    "$325.0M of share repurchase authorisation remains through April 2028, after 3.0M shares bought for $175.0M in FY2026."
  ],
  "body_markdown": "## Current Thesis\n\nThe binary flagged in the last note resolved in the operators' favour. On **2026-08-06** Haemonetics reported Q1 FY2027 (quarter ended 2026-06-27) revenue of **$339.4M, +5.6% reported and +5.9% organic**, against consensus of $327.89M, with adjusted EPS **$1.14** versus $1.08 expected and GAAP diluted EPS $0.72. The line the bear case rested on turned: **Interventional Technologies printed $59.9M, +2.5% reported and +2.8% organic**, after −10.3% organic in Q4 FY2026. Management then raised FY2027 reported revenue growth to **+5–8% from +4–7%** and organic to **+4–7% from +3–6%**, with the dollar range moved to $1.401B–$1.441B from $1.410B–$1.427B. Six desks repriced within 48 hours. Price made a new 52-week high of **$91.34** and closed **$90.80 on 2026-08-14**, 0.6% under that high, up 61.3% over three months with RSI(14) at 73.8.\n\nThat changes what is on offer. Through June and July the leg was \"plasma re-acceleration and a hospital turn are underappreciated.\" As of 2026-08-06 both are reported facts inside a raised guide, the sell-side carries **8 buy / 3 hold / 0 sell**, and the next company-scheduled event is roughly eleven weeks out. The narrative is **maturing** — the narrative still works (new high after the print) but the controversy that paid for it was settled on a single dated release, and the repricing was compressed into 2026-08-06/07.\n\n## Bull Case\n\n- **The disputed segment inflected.** Interventional Technologies +2.8% organic in Q1 FY2027 versus −10.3% organic in Q4 FY2026 and −9% for FY2026. CEO Christopher Simon's 2026-05-07 claim that the headwinds were \"lapped or reduced\" got its first test and passed.\n- **Plasma kept compounding under the new segment wrapper.** Plasma revenue **$155.5M, +7.2% reported / +8.2% organic**, inside Apheresis of $191.3M (+6.0% organic), with the Persona PLUS rollout cited on the 2026-08-06 call.\n- **MedSurg carried its own weight:** $148.1M, +6.0% reported / +5.9% organic, with Blood Management Technologies at $88.1M, +8.1% organic.\n- **Guidance moved up on both ends the same day**, which is the estimate support the late-July advance had been running ahead of: reported +5–8%, organic +4–7%, Apheresis FY2027 outlook lifted to low-to-mid-single-digit growth.\n- **Deleveraging is visible in the filing.** Q1 operating cash flow $52M; cash $223.4M against total debt $1,174.2M and net debt $950.8M; management cited $100M of debt repayment during and after the quarter. $325.0M of buyback authorisation remains through April 2028, after 3.0M shares repurchased for $175.0M in FY2026.\n- **Clinical data landed three days before the print:** a 1,623-patient retrospective Emory cohort published 2026-08-03 showed VASCADE MVP XL at 92.5% same-day discharge, 1.2% overall vascular complications and median hemostasis of two minutes.\n- **Targets moved above spot at most desks:** Raymond James to $105 from $90, BTIG to $96, Baird to $96 from $88, Barrington to $95 from $89 (2026-08-06/07).\n\n## Bear Case\n\n- **The beat was revenue-led; margin stood still.** Gross margin 59.8%, flat year over year. Adjusted operating margin 16.9%, up only 10bps — against an FY2027 guide of +50–100bps. Adjusted EPS grew 3.6% while revenue grew 5.6%.\n- **GAAP profit went backwards:** net income $33.0M, −3.0% YoY, on operating income of $57.5M (+6.7%).\n- **Cash conversion started the year below plan:** free cash flow conversion 75% of adjusted net income in Q1 versus a ~80% FY2027 target and 89% delivered in FY2026.\n- **The guide widened as well as rose.** The bottom of the FY2027 revenue range fell to $1.401B from $1.410B while the top went to $1.441B — a wider band around a consensus that sat at roughly $1.402B.\n- **Blood Center is still shrinking inside Apheresis:** Other Apheresis $35.8M, −2.4%, and it is guided to a mid-single-digit FY2027 decline. Reported Apheresis growth will keep reading below the plasma line that drove the re-rate.\n- **Two of the desks closest to the print stayed on the sidelines**, with Citi at Neutral/$92 (from $79) and JP Morgan at Neutral/$86 (2026-08-07) — the latter below the 2026-08-14 close of $90.80.\n- **Roughly 2 points of FY2027 reported growth come from a 53rd week**, so reported and organic diverge all year and the reported line flatters the comparison.\n\n## Setup & Price Structure\n\n- Reference close **$90.80 (2026-08-14)**; 52-week high **$91.34**, 0.6% above the close. The prior high of $87.32 (as of 2026-07-31) was taken out after the print, so the structure is intact and extended at the same time.\n- Three-month return **+61.3%**; RSI(14) **73.8**. The pre-print reference close was $85.54 on 2026-07-31, above a 50-day average of $74.52 and a 200-day of $67.63 on that date.\n- The relevant shelf is the pre-earnings zone: price traded $77.40–$78.78 on 2026-07-21/22, broke out on 2026-07-28/29 on 802,209 and 893,393 shares, then closed $85.54 into the print. A move back under the print reaction returns price to that congestion.\n- **Crowding observables, stated as observables:** six price-target raises inside 48 hours of the 2026-08-06 release; zero sell ratings across 11 covering analysts; short interest 2.70M shares, 6.03% of float as of 2026-07-31; seven directors each received 2,538 RSUs on 2026-07-24 (annual board grant) and no open-market insider sales surfaced in Form 4 filings around the print; no equity issuance — the capital action running is repurchase, with $325.0M authorised through April 2028.\n- **No dated company catalyst inside the next 30 days.** The gap between a resolved print and the next one is where a crowded post-earnings tape has nothing to absorb supply.\n\n## Catalyst Calendar (next 30 days)\n\n- **No scheduled company event identified between 2026-08-16 and 2026-09-15.** The Q1 print (2026-08-06) and the Q1 FY2027 10-Q (filed 2026-08-06) are both behind.\n- **Undated, under FDA review:** PerQseal Elite. FY2027 guidance assumes zero revenue from it, so clearance is incremental to the raised plan.\n- **~2026-10-06 (est.):** the 90-day downside catalyst watch Citi opened 2026-07-08 runs out. Citi raised its target to $92 on 2026-08-07 while holding Neutral.\n- **~2026-11-05 (est.):** Q2 FY2027 results — the first quarter that has to hold the Interventional Technologies turn and show margin moving toward the +50–100bps FY guide.\n\n## Elapsed catalysts\n\n- **Open-ended, opened 2025-09-26:** Commerce Section 232 investigation into imported medical devices, equipment and consumables. Tariffs are already an FY2027 margin assumption; a determination can land inside the window. *(passed 334d ago)*\n\n## What Would Change Our Mind\n\nThe structural break is a second quarter of MedSurg growth without margin: adjusted operating margin at or below 16.9% again, with free cash flow conversion still tracking under the ~80% FY2027 target, would say the raised revenue guide is being bought with spend rather than operating leverage. The clean, gradeable version of that break is **a weekly close below $85**, which surrenders the entire 2026-08-06 print reaction and puts price back into the pre-earnings $77–$85 congestion, with the 50-day (rising, $74.52 as of 2026-07-31) underneath. A second condition sits at the Q2 print: Interventional Technologies back to negative organic growth, or the +4–7% organic FY range left untouched after a soft quarter, would remove the estimate support that arrived on 2026-08-06. Finally, if the theme flips to saturated — coverage saturated at zero sell ratings with price above the median published target and no new operating datapoint — the remaining bid is multiple, and multiple is what the medtech group takes back first.\n\n## Correlation Notes\n\n- Beta 0.52 (as of 2026-07-31). HAE trades as defensive medtech with an idiosyncratic plasma driver; it is not a proxy for the AI-capex complex and does not need index beta to work.\n- Group context matters for the multiple leg: medtech ran a −8.3% median YTD return through Q2 2026 against +14.1% for the S&P 500 that quarter, and BofA's 2026-07-29 raise to $93 explicitly cited \"higher peer valuations.\" A renewed group de-rate hits the part of this move that came from comparables.\n- Plasma volumes correlate with fractionator collection budgets — the CSL relationship already cost a reported revenue step, and organic ex-CSL was the metric that carried FY2026.\n- Section 232 device tariffs are a sector-wide input, not a name-specific one; any determination re-rates the whole imported-device cost base at once.",
  "first_seen": "2026-06-07",
  "last_analyzed": "2026-08-16T17:02:59+00:00",
  "last_synthesized": "2026-08-16",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}